AEON Biopharma, Inc. (AEON)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-03

Key Insights

John Bencich, the Chief Financial Officer of AEON Biopharma, Inc. (AEON), was granted 754,717 shares of Class A common stock on April 2, 2026, vesting in equal installments over four years.
This insider grant suggests the company is incentivizing its executive leadership to drive long-term value creation for shareholders.
The significant equity award to the CFO, representing a substantial stake in the company, aligns his interests with those of investors.

Current Report Filed: 2026-03-30

Key Insights

AEON Biopharma, Inc. reported its financial results for the year ended December 31, 2025, indicating the company's performance during that period.
The filing does not provide any additional details about the company's financial condition, operations, or material events that occurred during the reported timeframe.
Without more information in the 8-K filing, it is difficult to assess the significance or implications of the reported financial results for AEON Biopharma's investors.

Current Report Filed: 2026-03-09

Key Insights

AEON Biopharma has appointed John Bencich as its new Chief Financial Officer, strengthening the company's executive leadership team as it advances key regulatory and financing milestones.
Bencich brings over 25 years of financial and leadership experience in the biotechnology and life sciences sectors, which could help AEON execute on its strategic initiatives.
The employment agreement provides Bencich with a competitive compensation package, including a base salary, annual bonus opportunity, and severance benefits in the event of termination without cause or resignation for good reason, especially in the context of a change in control.

Current Report Filed: 2026-01-21

Key Insights

AEON Biopharma has entered into an exchange agreement with Daewoong Pharmaceutical to satisfy its outstanding senior secured convertible notes, which will result in the issuance of new common stock, warrants, and a new convertible note.
The company held a special meeting of stockholders on January 21, 2026, where shareholders approved the PIPE financing proposal, the exchange proposal with Daewoong, and the amended 2023 Incentive Award Plan.
Following the exchange and stockholder approvals, AEON Biopharma has 24,024,282 shares of common stock outstanding as of January 21, 2026.

Current Report Filed: 2026-01-12

Key Insights

AEON Biopharma is an emerging growth company, which means it may have more flexibility in financial reporting and less stringent disclosure requirements.
The company has filed an 8-K to disclose the release of a corporate presentation on its investor relations website, which may provide additional insights into its business and financial performance.
As an 8-K filing, this event is likely to be of moderate significance to investors, as it represents the disclosure of potentially material information about the company.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.